Company: TVRD
Filing Date: 2025-01-17
Form Type: 425
Source: 0001104659-25-004519
Chunk: 4

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-17
Form: 425
Chunk 4
---
, except as required by law.

Additional Information and Where to Find It

This Current Report on Form 8-K relates to a
proposed acquisition transaction between the Company and Tvardi. In connection with the proposed transaction, the Company has filed
with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 that contains
a preliminary proxy statement and preliminary prospectus. The Company may also file other documents with the SEC regarding the
proposed transaction. THE COMPANY URGES INVESTORS AND STOCKHOLDERS TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY
BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, TVARDI, THE PROPOSED TRANSACTION AND RELATED
MATTERS. Stockholders are and will be able to obtain free copies of the preliminary proxy statement, preliminary prospectus and
other documents filed by the Company with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov.
In addition, stockholders are or will be able to obtain free copies of the preliminary proxy statement, preliminary prospectus and
other documents filed by the Company with the SEC by contacting Investor Relations by email at investor@caratherapeutics.com.
Stockholders are urged to read the preliminary proxy statement, preliminary prospectus and the other relevant materials when they
become available before making any voting or investment decision with respect to the proposed transaction.

Participants in the Solicitation

The Company and Tvardi, and each of their
respective directors and executive officers and certain of their other members of management and employees, may be deemed to be
participants in the solicitation of proxies in connection with the proposed transaction. Information about the Company’s
directors and executive officers, consisting of Helen M. Boudreau, Jeffrey L. Ives, Ph.D., Christopher Posner, Susan Shiff, Ph.D.,
Martin Vogelbaum, Lisa von Moltke, M.D., Ryan Maynard and Scott Terrillion, including a description of their interests in the
Company, by security holdings or otherwise, can be found under the captions, “Security Ownership of Certain Beneficial Owners
and Management,” “Executive Compensation” and “Director Compensation” contained in the definitive
proxy statement on Schedule 14A for the Company’s 2024 annual meeting of stockholders, filed with the SEC on April 22, 2024
(the “2024 Cara Proxy Statement”). To the extent that the